Source link : https://www.newshealth.biz/health-news/mirikizumab-shows-promise-for-moderate-to-severe-crohns/
WASHINGTON, DC — The selective interleukin (IL)–23p29 monoclonal antibody mirikizumab demonstrated safety and efficacy in people with moderate to severe Crohn’s disease compared with placebo up to 52 weeks, according to results of the phase 3 randomized, double blind, treat-through VIVID-1 study. Bruce E. Sands, MD, chief of gastroenterology at the Icahn School of Medicine […]
Author : News Health
Publish date : 2024-05-20 18:33:09
Copyright for syndicated content belongs to the linked Source.
Categories